$AVBP News

ArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer Patients

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

Why ArriVent BioPharma Stock Is In Focus After Trial Failure And Legal Probe

ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

ArriVent BioPharma To Present Initial Safety, Efficacy Results Of Its Phase 1 Trial Of CDH17-Targeted ADC ARR-217 In Participants With Gastrointestinal Cancers At ESMO Congress 2026

B. Riley Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target

ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002

ArriVent BioPharma Doses First Patient In Phase 1 Trial Of Dual-Target ADC ARR-002 For Ovarian And Endometrial Cancer

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Lowers Price Target to $27

Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails

Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20

ArriVent’s stock plummets on Phase III NSCLC trial failure

Truist Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18

Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18

BTIG Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29

ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low

AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’

ArriVent BioPharma: Phase 3 Failure Resets The Investment Case (Rating Downgrade)